Abbott Laboratories (ABT)
| Market Cap | 229.65B |
| Revenue (ttm) | 43.11B |
| Net Income (ttm) | 13.93B |
| Shares Out | 1.74B |
| EPS (ttm) | 7.97 |
| PE Ratio | 16.55 |
| Forward PE | 24.40 |
| Dividend | $2.36 (1.79%) |
| Ex-Dividend Date | Jul 15, 2025 |
| Volume | 4,635,312 |
| Open | 132.30 |
| Previous Close | 132.20 |
| Day's Range | 131.65 - 133.17 |
| 52-Week Range | 110.86 - 141.23 |
| Beta | 0.69 |
| Analysts | Strong Buy |
| Price Target | 143.67 (+8.88%) |
| Earnings Date | Oct 15, 2025 |
About ABT
Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism,... [Read more]
Financial Performance
In 2024, Abbott Laboratories's revenue was $41.95 billion, an increase of 4.59% compared to the previous year's $40.11 billion. Earnings were $13.35 billion, an increase of 134.19%.
Financial StatementsAnalyst Summary
According to 18 analysts, the average rating for ABT stock is "Strong Buy." The 12-month stock price target is $143.67, which is an increase of 8.88% from the latest price.
News
Inside Abbott's big bet on the future of healthcare
Abbott CEO highlights the company's devices that could make healthcare faster and easier.
Abbott to take $200 million tariff hit: What it means for patients
Abbott's CEO explains what tariffs mean for the company and its patients. Transcript: CAROLINE WOODS: So while you're working on all of that, you're also having to plan for and account for tariffs tha...
Abbott's Navitor™ TAVI System Receives CE Mark for Expanded Indication to Treat More People With Aortic Stenosis
Navitor is now approved as a minimally invasive alternative to surgery for patients in Europe with symptomatic, severe aortic stenosis (a common and life-threatening heart valve disease) who are at lo...
Abbott CEO reveals the biggest disruptions in healthcare
An inside look into Abbott's momentum across diagnostics and devices, tariff impacts, and how AI will transform healthcare within five years. Transcript: CAROLINE WOODS: Joining me now, Robert Ford, C...
Best Dividend Aristocrats For September 2025
Dividend Aristocrats have shown mixed 2025 performance, with some delivering double-digit gains and others lagging, but overall stability remains a hallmark. Dividend growth is robust, with 53 of 69 A...
Best Dividend Kings: August 2025
Dividend Kings underperformed SPY year-to-date but are showing stronger gains in August, with several stocks achieving double-digit returns in 2025. Fifteen Dividend Kings currently appear undervalued...
Abbott and Big Ten Conference Rally Students, Alumni, and Fans to Save Lives and Win $1 Million for Their School by Donating Blood This College Football Season
All 18 Big Ten universities will go head-to-head in Year 2 of the nationwide challenge, the 'We Give Blood' drive, to inspire the most blood donations from students, alumni, and fans with the winning ...
Abbott India's profit climbs on healthy pharmaceutical demand
Drugmaker Abbott India reported an 11.5% rise in first-quarter profit on Tuesday, driven by healthy sales in its mainstay pharmaceuticals segment.
Abbott Laboratories Q2 Earnings: Dividends Don't Lie
Abbott's Q2 performance reflects some evenness and the potential headwinds from macroeconomic uncertainties. However, short-term issues like tariffs and drug price control do not fundamentally alter A...
Pres. Trump's push to lower drug prices 'is a good starting point', says Dr. Scott Gottlieb
Former FDA Commissioner Dr. Scott Gottlieb joins 'Squawk Box' to discuss news of President Trump ordering pharma companies to lower U.S. drug prices in the next 60 days, the move to tiered pricing glo...
President Trump demands drugmakers slash prices within 60 days
CNBC's Joe Kernen reports on the latest news.
Best Dividend Aristocrats For August 2025
Dividend Aristocrats are outperforming SPY in July but still trail year-to-date; select Aristocrats delivered double-digit gains and strong dividend growth. 47 of 69 Aristocrats raised dividends in 20...
Five years after COVID, pharma shares languish in US policy limbo
Global healthcare stocks have not been this cheap in decades and fund inflows into the sector are picking up, yet the shares remain in the doldrums, highlighting uncertainty over drug pricing policies...
Best Dividend Kings: July 2025
14 Dividend Kings continue to outperform the S&P 500 in 2025. Dividend growth remains healthy, with one recent increase and a collective 2025 growth rate of 5.23%. Seventeen Dividend Kings currently a...
These Analysts Revise Their Forecasts On Abbott Following Q2 Results
Abbott Laboratories ABT reported better-than-expected sales and profits in the second quarter, but dialed back earnings and growth projections for the rest of the year.
Abbott Laboratories: What's Behind The Q2 Earnings Slump?
ABT, which had been outperforming the healthcare cohort from the S&P 500 and the S&P 500 itself all through this year, has slumped dramatically following yesterday's Q2 earnings. While Q2 sales beat e...
Abbott CEO Robert Ford goes one-on-one with Jim Cramer
Abbott Chairman and CEO Robert Ford joins 'Mad Money' host Jim Cramer to talk quarterly results, lowering its full-year guidance, sale trends, and more.
Didn't see the recovery in China we were expecting, says Abbott Labs CEO on lowering guidance
Abbott Chairman and CEO Robert Ford joins 'Mad Money' host Jim Cramer to talk quarterly results, lowering its full-year guidance, sale trends, and more.
Abbott Laboratories CEO calls post-earnings stock decline 'a little bit of an overreaction'
Abbott Laboratories CEO Robert Ford unpacked his company's latest quarterly report in a Thursday interview with CNBC's Jim Cramer, saying that Wall Street's reaction to the results was too extreme. "I...
Abbott Laboratories (ABT) Q2 2025 Earnings Call Transcript
Abbott Laboratories (NYSE:ABT) Q2 2025 Results Conference Call July 17, 2025 9:00 AM ET Company Participants Michael Comilla - Vice President of Investor Relations. Philip P. Boudreau - CFO & Executi...
Abbott Laboratories Issues Weak Earnings Forecast, Joins MP Materials And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
U.S. stock futures were mostly lower this morning, with the Dow futures falling around 0.2% on Thursday.
Abbott Labs Stock Dives After Earnings Miss. Why Rising Sales Fail to Lift Shares.
Abbott Laboratories stock falls even as the company reports second-quarter sales that top expectations.
Abbott beats quarterly profit estimates on medical devices demand
Abbott beat Wall Street estimates for quarterly profit on Thursday, driven by strong demand for its medical devices including continuous glucose monitors.
Abbott Reports Second-Quarter 2025 Results
Second-quarter reported sales growth of 7.4 percent; organic sales growth of 6.9 percent or 7.5 percent excluding COVID-19 testing-related sales1 Second-quarter GAAP diluted EPS of $1.01; adjusted dil...
Abbott Earnings Are Imminent; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call
Abbott Laboratories ABT will release earnings results for the second quarter, before the opening bell on Thursday, July 17.